One in four patients switch RA drugs in first year, study shows

Researchers have found that changing up therapies is common because of lack of efficacy

About one quarter of patients prescribed a first-line TNF inhibitor for rheumatoid arthritis will switch to another agent within the first 12 months of therapy, Australian researchers have found.

And the most common reason for stopping or changing to another biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) was lack of efficacy rather than adverse events, their study shows.

The authors also suggest that some biologics including rituximab and tocilizumab have a much